INDV - Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
INDV - Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
10 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, a successful postpartum depression launch, and a promising pipeline. The planned Indivior merger aims to accelerate diversification and cash flow, supporting further R&D and M&A.Based on Supernus P…
Indivior, Supernus announce proposed all-stock merger
Indivior and Supernus say they will combine in an all-stock, tax-free merger of equals, with expected annual cost synergies of $125 million.
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better se
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company. The combined business will operate as Supernus and trade on the Nasdaq Global Market
Supernus, Indivior Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
INDV Indivior Pharmaceuticals Inc: Supernus must pay Co termination fee of $101M if the merger agreement is terminated under certain circums
INDV Indivior Pharmaceuticals Inc: Supernus must pay Co termination fee of $101M if the merger agreement is terminated under certain circumstances
Supernus Pharmaceuticals Merges With Indivior
Supernus stockholders get Indivior shares
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significa
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significant scale Supernus Pharmaceuticals Inc - combined entity to be named Supernus, Inc. and Jack khattar to serve as President and Chief Executive Officer - Definitive agreement to comb
Supernus, Indivior to Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader